Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2002 September;41(3) > Minerva Pneumologica 2002 September;41(3):101-12

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA PNEUMOLOGICA

A Journal on Diseases of the Respiratory System


Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Pneumologica 2002 September;41(3):101-12

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: Italian

Aspirin-intolerance: present clinical and pathogenetical features

Schiavino D., Buonomo A., Nucera E., Patriarca G.


PDF  


Aspirin-intolerance is a clinical syndrome whose increasing frequency is due to the larger use of this drug all over the world. The main reported side-effects con be distinguished in organ toxicity (gastrointestinal bleeding, epigastric pain) and allergic-like reactions. The pathogenetic mechanism of these reactions has not been well clarified, but it has been hypothesised that it can be due to an anomalous inhibition of cyclo-oxygnase (COX) in predisposed subjects. The symptoms of aspirin-intolerance are mainly cutaneous (urticaria, angioedema), respiratory (asthma, rhinitis) and rarely anaphylactic. The association of aspirin-intolerance, intrinsic bronchial asthma and nasal polyposis constitutes the ''aspirin disease''. It should be pointed out that: patients affected by aspirin-intolerance are at a high risk of adverse reactions to other non steroidal antiinflammatory drugs (NSAIDs) that inhibit both COX-1 and COX-2; patients with nasal polyposis and intrinsic bronchial asthma are at higher risk to develop an adverse reaction to aspirin or other NSAIDs than normal subjects; in patients with ASA intolerance, selective COX-2 inhibitors (celecoxib, rofecoxib), relative inhibitors of COX-2 and minor inhibitors of COX-1 (meloxicam, nimesulide, acetaminophen) are generally well tolerated (in 85-90% of cases); in patients with nasal polyposis, a topic intranasal treatment with lysine-acetylsalicylate inhibits the growth of nasal polyps and delays their relapse after surgery.

top of page

Publication History

Cite this article as

Corresponding author e-mail